Strategic partnership with Stem Cell Theranostics in joint CIRM grant application

Novoheart has entered into a strategic partnership with Stanford biotech startup Stem Cell Theranostics (SCT), based in the Bay Area, for a joint grant application to the California Institute of Regenerative Medicine (CIRM).

SCT is a discovery stage biotechnology company with an exclusive partnership with Stanford University Cardiovascular Institute, with strengths in genetic and drug-induced heart disease. SCT’s unique access to patient samples and expertise in the stem cell space, combined with Novoheart’s world-class cardiac tissue engineering capabilities, yields a powerful platform for studying heart diseases.

For more information on SCT, please refer to the official website.